Chi-Med Starts China Phase I/II Trial of Novel FGFR Inhibitor

Hutchison China MediTech (Chi-Med) has dosed the first patient in a China Phase I/II trial of HMPL-453. HMPL-453 is a small molecule inhibitor of fibroblast growth factor receptor (FGFR). Earlier this year, HMPL-453 began its first Phase I trial in Australia, the eighth Chi-Med molecule to begin clinical trials. Last week, Chi-Med reported the CFDA accepted the company's New Drug Application for its lead drug, fruquintinib, a VEGFR inhibitor, indicated for colorectal cancer. More details.... Stock Symbols: (AIM/NSDQ: HCM) Share this with colleagues: // //